Source comparison
BPC-157 Research Cardiovascular Considerations: Method Comparison
Subcutaneous (200–300 mcg daily split dose) 4–6 hour half-life, stable levels 40–55% infarct size reduction in ischemia models No elevation in platelet aggregation; D-dimer stable Weekly BP, monthly D-dimer, baseline coagulation panel Gold standard for researc
This comparison does not assign a generated winner or score.
- Subcutaneous (200–300 mcg daily split dose)
- 4–6 hour half-life, stable levels
- 40–55% infarct size reduction in ischemia models
- No elevation in platelet aggregation; D-dimer stable
- Weekly BP, monthly D-dimer, baseline coagulation panel
- Gold standard for research. Predictable kinetics, lowest risk profile, easiest monitoring
- Intramuscular (single daily 300 mcg)
- Peak-and-trough pattern, less stable
- Similar efficacy but inconsistent dosing curve
- Mild transient D-dimer elevation (not clinically significant)
- Same as subcutaneous
- Acceptable alternative but less controlled plasma levels. Reserve for participants unable to self-administer subcutaneous
- Intravenous (acute 500 mcg bolus)
- Immediate peak, rapid clearance
- Strongest acute cardioprotection in reperfusion models
- Transient hypotension from NO surge
- Continuous cardiac monitoring required
- Research setting only. Unsuitable for outpatient protocols due to BP drop risk
- Oral (experimental, not bioavailable)
- Degraded in GI tract, negligible absorption
- No measurable cardiovascular effect
- None (no systemic exposure)
- Not applicable
- Ineffective route. Gastric enzymes destroy the peptide before absorption